Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
ID: 346550Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346550

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-130.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This initiative seeks to support translational and clinical research that enhances understanding of drug actions, develops novel therapeutics, and improves the safety and efficacy of medications for these populations. The funding opportunity encourages interdisciplinary collaboration and innovative research approaches, including drug delivery systems and the integration of artificial intelligence in pediatric medicine. Interested applicants can find more details and submit proposals electronically via Grants.gov by May 7, 2026, with inquiries directed to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-130-Full-Announcement.html
    PAR-23-130.html
    The Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) intended to promote translational research in maternal and pediatric pharmacology and therapeutics. This initiative, supported by various NIH institutes including NICHD, NIAID, NIDA, and NIMH, aims to develop innovative tools and therapies to enhance precision medicine for pregnant and lactating individuals, as well as children. Key goals include improving understanding of drug actions, addressing metabolic changes during pregnancy, and discovering safer medications. The funding opportunity encourages research on drug delivery systems, pharmacokinetic models, and the integration of artificial intelligence in pediatric medicine. Applications are welcomed from diverse organizations, emphasizing interdisciplinary collaboration and alignment with previous federal mandates like the Best Pharmaceuticals for Children Act. The application process requires adherence to specific guidelines, and proposals should be submitted electronically via Grants.gov by set deadlines. The funding is contingent upon the quality of applications and available resources, with maximum project durations of five years. This NOFO reflects a governmental priority to address significant gaps in maternal and pediatric therapeutics research, promoting safer healthcare outcomes for these populations.
    Similar Opportunities
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating individuals, and children. This initiative seeks to support translational and clinical research that develops novel therapeutic tools, enhances understanding of drug mechanisms, and improves medication safety and efficacy for these vulnerable populations. The program emphasizes interdisciplinary collaboration to address unmet therapeutic needs and promote better health outcomes in maternal and pediatric medicine. Applications will be accepted starting January 5, 2025, with a closing date of May 7, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-110.html.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity (PAR-23-037) aimed at promoting multisite clinical trials and observational studies focused on women, children, pregnant and lactating individuals, and persons with disabilities. The initiative seeks to enhance the rigor and reproducibility of clinical trial protocols, facilitate data sharing, and increase the involvement of diverse populations in research through the utilization of NICHD-supported Network infrastructure. This funding opportunity supports projects for up to five years, with budgets reflecting actual needs, and requires a rigorous pre-application process starting with a Letter of Inquiry. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with ongoing application cycles and a close date set for May 7, 2026.
    Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R41 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at the development of medical devices for the pediatric population (ages 0-21) affected by substance use and addiction. This initiative invites Small Business Innovation Research (SBIR) grant applications that focus on innovative research and development of therapeutic and diagnostic devices, addressing critical gaps in pediatric medical device availability. With a total funding commitment of up to $1 million for two to three awards, each grant can provide a maximum of $400,000, and applications are due by February 26, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Medical Devices for Pediatric Population Affected by Substance Use and Addiction," aimed at supporting small businesses through the Small Business Innovation Research (SBIR) grant program. This initiative invites applications for the research and development of medical devices specifically designed for individuals aged 0-21 who are affected by substance use and addiction, addressing a critical gap in pediatric healthcare. The program seeks innovative proposals for digital therapeutics, diagnostic tools, and wearable devices, with an expected funding allocation of approximately $2 million to support four or five Phase I awards, each up to $400,000. Applications are due by February 26, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities" through a cooperative agreement mechanism. This initiative aims to utilize NICHD clinical research network infrastructure to support multisite, investigator-initiated clinical trials and observational studies, focusing on improving health outcomes for vulnerable populations. The funding opportunity emphasizes the importance of diverse participant enrollment and collaboration, requiring applicants to develop a Plan for Enhancing Diverse Perspectives and a Data Management and Sharing Plan. The maximum funding amount is $6,250,000, with a project period of up to seven years, and applications are due by November 15, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-25-311.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at advancing research in novel screening methods and therapeutic interventions for genetic conditions identified through newborn screening. This initiative encourages the development of innovative screening assays, the use of artificial intelligence, and the exploration of socio-economic implications related to newborn screening, with a focus on conditions that may benefit from early detection and treatment. The grant supports long-term research projects (R01) and is open to a diverse range of applicants, including higher education institutions and community-based organizations, with applications accepted until November 16, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.html.